Europe Research Roundup: BBVA, SSE, Biomerieux, Merck, Novo Nordisk

Hexaom SA

20/03/2014 07:27

March 20 (Reuters) - Securities analysts revised their ratings and price targets on several 
European companies, including BBVA and SSE, on Thursday.  
     
    HIGHLIGHTS 
    * BBVA  BBVA.MC : SocGen cuts to sell from hold rating; cuts target to 8 euros   
    * SSE  SSE.L : Morgan Stanley raises to overweight from underweight rating   
    * Biomerieux  BIOX.PA : UBS adds to European Medtech & Biotech least preferred list         
       
Following is a summary of research actions on European companies reported by Reuters on 
Thursday. Stock entries are in alphabetical order.    
     
    * BBVA  BBVA.MC : SocGen cuts to sell from hold rating  
    * BBVA  BBVA.MC : SocGen cuts target price to 8 euros from 8.8 euros 
    * Bechtle  BC8G.DE : Commerzbank raises price target to 50 euros from 42 euros; rating hold 
    * Biomerieux  BIOX.PA : UBS cuts target price to 75 euros from 78 euros; rating neutral  
    * Biomerieux  BIOX.PA : UBS adds to European Medtech & Biotech least preferred list  
    * Centrica  CNA.L : Morgan Stanley raises target price to 345p from 340p;rating equal-weight 
    * Galenica  GALN.S : UBS removes from European Medtech & Biotech least preferred list 
    * Galenica  GALN.S : UBS retains neutral rating 
    * Grand City Properties  GYC.F : Berenberg raises target to 10 from 9.15 euros; rating buy 
    * Heidelbergcement  HEIG.DE : S&P Capital IQ raises target to 67 from 63 euros; rating buy 
    * Krones  KRNG.DE : S&P Capital IQ raises price target to 76 euros from 72 euros; rating buy 
    * Ladbrokes  LAD.L : Morgan Stanley cuts target price to 130p from 150p; rating equal-weight 
    * Paddy Power  PAP.I : Morgan Stanley cuts target to 60 from 63 euros; rating equal-weight 
    * SSE  SSE.L : Morgan Stanley raises to overweight from underweight rating  
    * SSE  SSE.L : Morgan Stanley raises target price to 1735p from 1280p  
    * William Hill  WMH.L : Morgan Stanley cuts target to 430p from 455p; rating overweight  
 
  
 
 (Compiled by Rachel Chitra in Bangalore) 
 ((rachel.chitra@thomsonreuters.com)(within U.S. +1 646 223 8780)(outside U.S. +91 80 
67496149)(Reuters Messaging: rachel.chitra.reuters.com@reuters.net)) 
 
Keywords: RESEARCH EUROPE/